Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Reboxetine Adjuvant Therapy in Patients With Schizophrenia Showing a Suboptimal Response to Clozapine: A 12-Week, Open-Label, Pilot Study
Abstract The present 12-week open-label uncontrolled trial was aim ed to explore the efficacy of reboxetine add-on pharmacotherapy on clinical symptoms and cognitive functioning in 15 patients with schizophrenia with suboptimal response ( mean [ SD ] Brief Psychiatric Rating Scale baseline total score , 32.2 [ 5.4 ] ) despite receiving clozapine monotherapy at the highest tolerated dosage . The results obtained evidence d that reboxetine at a dosage of 4 mg/d mildly reduced only depressive symptoms ( Calgary Depression Scale for Schizophrenia : P = 0.035 , Cohen d = 0.7 ) , whereas worsening of performances on phonemic fluency ( P = 0.012 , Cohen d = 0.5 ) was observed . After Bonferroni correction , changes at the Calgary Depression Scale for Schizophrenia and at the Verbal Fluency Task were not further confirmed . The results obtained indicate that reboxetine seemed to be scarcely effective for reducing clinical symptoms in patients with schizophrenia who have had an incomplete clinical response to clozapine .  Regarding cognitive functioning , in our sample , a trend to experience cognitive impairment in the examined domains was observed , as confirmed by a mild worsening of performances on cognitive tasks . Schizophrenia is a heterogeneous disorder with regard to pathophysiology ; therefore , data reflecting the mean response of a sample of patients may fail to reveal therapeutic effects . More research is needed to better identify subgroups of patients with peculiar features , which may account for responsivity to experimental medications and augmentation strategies
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .